Medicine and Health

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

A. J. Sanyal, L. M. Kaplan, et al.

Retatrutide, a novel triple agonist, has shown remarkable efficacy in significantly reducing liver fat among participants suffering from metabolic dysfunction-associated steatotic liver disease. This 24-week study led by Arun J. Sanyal and colleagues highlights the potential transformative effects of this treatment, with reductions in liver fat reaching as high as 82.4%.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

H. R. C. Shanks, K. Chen, et al.

Medicine and Health

Association between fast eating speed and metabolic dysfunction-associated steatotic liver disease: a multicenter cross-sectional study and meta-analysis

M. Zhang, X. Sun, et al.

Medicine and Health

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

A. H. Diacon, C. E. B. Iii, et al.

Medicine and Health

Joint association of sleep quality and physical activity with metabolic dysfunction-associated fatty liver disease: a population-based cross-sectional study in Western China

Y. Wang, Q. Zhao, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny